[1] The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. ACOG Committee Opinion. SGO No.716, Nov 2017.
[2] Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020 Jan;76(1):151-156. doi: 10.1111/his.13977.
[3] Substrate curvature induces fallopian tube epithelial cell invasion via cell-cell tension in a model of ovarian cortical inclusion cysts. Fleszar AJ, Walker A, Kreeger PK, Notbohm J.Integr Biol (Camb). 2019.
[4] The Extracellular Matrix of Ovarian Cortical Inclusion Cysts Modulates Invasion of Fallopian Tube Epithelial Cells. Fleszar AJ et al. 2018.
[5] Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy. Park KJ et al. 2018.
[6] Two types of ovarian cortical inclusion cysts: proposed origin and possible role in ovarian serous carcinogenesis. Banet N, Kurman RJ.Int J Gynecol Pathol. 2015.
[7] Serous ovarian tumors. Diebold J.Pathologe. 2014.
[8] Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015. van der Hel OL, Timmermans M, van Altena AM, Kruitwagen RFPM, Slangen BFM, Sonke GS, van de Vijver KK, van der Aa MA.Eur J Cancer. 2019.
[9] Detailed overview on rare malignant ovarian tumors. Aust S et al.Bull Cancer. 2020.
[10] Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects. Boussios S, Moschetta M, Zarkavelis G, Papadaki A, Kefas A, Tatsi K.Crit Rev Oncol Hematol. 2017.
[11] Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis. Gibbs J, Mei S, Economos K, Lee YC, Kanis MJ.Am J Obstet Gynecol. 2019.
[12] Гинекология: учебник / под ред. В.Г. Брусенко, Г.М. Савельевой. М.: ГЭОТАР-Медиа, 2013.
[13] C. Sourial, V. et al. Ovarian inguinal hernia: systematic review up to Feb 2018. Ann R Coll Surg Engl. 2020.
[14] Ovarian Cyst. Mobeen S, Apostol R.2020 Jul 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
[15] American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016.
[16] Савельева Г. М. и др. Гинекология. Национальное руководство //М.: ГЭОТАР-Медиа. – 2020.
[17] Герфанова Е.В., Ашрафян Л.А., Антонова И.Б., Алешикова О.И., Ивашина С.В. Опухоли женской репродуктивной системы. 2015.
[18] Munro MG, Critchley HOD, Fraser IS., FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.
[19] Sehemby M et al. Virilising ovarian tumors: a single-center experience. Endocr Connect. 2018 Dec;7(12):1362-1369.
[20] Guideline No. 404: Initial Investigation and Management of Benign Ovarian Masses. Wolfman W, Thurston J, Yeung G, Glanc P.J Obstet Gynaecol Can. 2020.
[21] Diagnosis of Ovarian Torsion: Is It Time to Forget About Doppler? Grunau GL, Harris A, Buckley J, Todd NJ.J Obstet Gynaecol Can. 2018.
[22] A review of ovary torsion. Huang C, Hong MK, Ding DC.Ci Ji Yi Xue Za Zhi. 2017 Jul-Sep;29(3):143-147.
[23] Ovarian Torsion. Guile SL, Mathai JK.2020 Nov 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
[24] Varras M Tsikini A Polyzos D et al. Uterine adnexal torsion: pathologic and gray-scale ultrasonographic findings. Clin Exp Obstet Gynecol. 2004.
[25] Clinical risk factors for ovarian torsion. Asfour V, Varma R, Menon P.J Obstet Gynaecol. 2015;35(7):721-5. doi: 10.3109/01443615.2015.1004524. Epub 2015.
[26] Friedrich L., Meyer R., Levin G. Management of adnexal mass: A comparison of five national guidelines //European Journal of Obstetrics & Gynecology and Reproductive Biology. – 2021.
[27] A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index Maria Lycke 1, Björg Kristjansdottir 2, Karin Sundfeldt 2Randomized Controlled Trial Gynecol Oncol. 2018.
[28] Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF). Bourdel N et al., Eur J Obstet Gynecol Reprod Biol. 2021.
[29] Guideline No. 403: Initial Investigation and Management of Adnexal Masses. Salvador S, Scott S, Glanc P, Eiriksson L, Jang JH, Sebastianelli A, Dean E.J Obstet Gynaecol Can. 2020.
[30] Comparison between Serum HE4 and CA125 as Tumor Markers in Premenopausal Women with Benign Pelvic Mass. Huang X, Wang Y, He X, Kang F, Luo L, Su Z, Ye H.Clin Lab. 2019.
[31] Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Zhang L, Chen Y, Wang K.Curr Probl Cancer. 2019.
[32] Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G.J Ovarian Res. 2019.
[33] HE4 in the differential diagnosis of ovarian masses. Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E.Clin Chim Acta. 2015.
[34] Sagi-Dain L, Lavie O, Auslander R, et al. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature. Int J Biol Markers 2015.
[35] Sagi-Dain L, Lavie O, Auslander R, et al. CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature. Int J Biol Markers 2015.